Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Pulmonary Hypertension: Controversial and Emerging Topics
Charnin, Jonathan E.

Mayo Clinic

Anesthesia & Analgesia | July 13, 2021 | Volume: 133 | Issue: 2 | Pages: e18-e19

10.1213/ane.0000000000005616 Get It

Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians
Giblon, Rachel , Kunneman, Marlene, Lee, Alexander I., Hargraves, Ian , Sivly, Angela , Burnett, Bruce , Gorr, Haeshik, Roldan, Victor D. Torres , Spencer-Bonilla, Gabriella, Shah, Nilay D. , Brito, Juan P. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, Haffke, Alexander, Stier, Amy, Thota, Anjali, Simpson, Benjamin , Zeballos‐Palacios, Claudia , Vanmeter, Derek , Behnken, Emma , Ting, Henry H. , Anderson, Joel, Inselman, Jonathan , Muegge, Jule , Fleming, Kirsten, Olive, Marc, Vang, Miamoua, Ferrara, Michael J. , Wambua, Mike , Organick, Paige, Cabalka, Renee, Poplau, Sara , Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , Kamath, Celia C , Branda, Megan E. , Hargraves, Ian G, Sivly, Angela L, Torres Roldan, Victor D , Brito, Juan P , Kamath, Celia , Lee, Alexander I., Bellolio, Fernanda , Jackson, Elizabeth A. , Burnett, Bruce, Noseworthy, Peter A. , Montori, Víctor M. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, LeBlanc, Annie , Hess, Erik P. , Hamilton, James, Fleming, Kirsten, Linzer, Mark , Suzuki, Takeki , Harvey, Lisa Anne , Stephens, Shannon W. , Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D.

Mayo Clinic

JAMA Network Open | July 13, 2021 | Volume: 4 | Issue: 7 | Pages: e2116009

10.1001/jamanetworkopen.2021.16009 | PMID 34255051 Get It

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William , Kohlschmidt, Jessica, Mrózek, Krzysztof , Carroll, Andrew J. , Eisfeld, Ann-Kathrin, Kolitz, Jonathan E. , Thakuri, Mohan C., Sutamtewagul, Grerk , Vij, Ravi , Byrd, John C. , Bloomfield, Clara D. , Stone, Richard M. , Byrd, John C. , Jacobson, Sawyer , Sutamtewagul, Grerk , Larson, Richard A , Stock, Wendy , Eisfeld, Ann‐Kathrin , Wang, Eunice S. , Stuart, Robert K. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 12, 2021 | Volume: 5 | Issue: 13 | Pages: 2775-2787

10.1182/bloodadvances.2021004233 | PMID 34251414 Get It

Abstract Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age <70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.
Copy Number Variation in Parkinson's Disease: An Update from Sub‐Saharan Africa
Müller-Nedebock, Amica Corda , Fawale, Bimbo , Westhuizen, Francois H. van der , Ross, Owen A. , Bardien, Soraya , Müller-Nedebock, Amica C , Ross, Owen A , Bardien, Soraya , Komolafe, Morenikeji Adeyoyin , Carr, Jonathan

Mayo Clinic

Movement Disorders | July 6, 2021 | Volume: 36 | Issue: 10 | Pages: 2442-2444

10.1002/mds.28710 | PMID 34228376 Get It

Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease
Keret, Ophir , Staffaroni, Adam M. , Ringman, John M. , Goh, Sheng‐Yang M., Wolf, Amy , Allen, Isabel Elaine , Salloway, Stephen , Chhatwal, Jasmeer P. , Reyes‐Dumeyer, Dolly , Bateman, Randall J. , Morris, John C. , Joseph‐Mathurin, Nelly , Perrin, Richard J. , Gordon, Brian A. , Xiong, Chengjie , Vöglein, Jonathan , Fougère, Christian la , Martins, Ralph N. , Sohrabi, Hamid R. , Taddei, Kevin , Villemagne, Victor L. , Fulham, Michael , Masters, Colin L. , Saykin, Andrew J. , Graff‐Radford, Neill R. , Weiner, Michael W. , Cash, David M. , Chrem, Patricio, Rabinovici, Gil D. , Rosen, Howard J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Saykin, Andrew J , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Morris, John C , Cash, David M , Rabinovici, Gil D , Cobigo, Yann , Brickman, Adam M. , Benzinger, Tammie L.S. , Ances, Beau M. , Jucker, Mathias , Schofield, Peter R. , Brooks, William S. , Ghetti, Bernardino , Jack, Clifford R. , Allegri, Ricardo , Su, Yi , Miller, Bruce L. , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 5, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12197 | PMID 34258377 Get It

Abstract Introduction Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD‐MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD‐MC and could help predict risk for dementia during trial enrollment. Methods We created a dementia risk score by entering standardized gray‐matter volumes from 231 DIAD‐MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD‐MC followed longitudinally. Results Our risk score separated asymptomatic versus demented DIAD‐MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD‐MC participants for prevention trials.
Abstract TMP42: Distinguishing Clinical and Radiologic Features of Non-Traumatic Convexal Subarachnoid Hemorrhage
Graff‐Radford, Jonathan , Fugate, Jennifer E. , Klaas, James P. , Brown, Robert D. , Flemming, Kelly D. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.tmp42 Get It

Introduction: Small case series have suggested that cerebral amyloid angiopathy (CAA) and reversible cerebral vasoconstriction syndrome (RCVS) are the most common causes of non-traumatic convexal SAH (cSAH). Our objective was to describe the spectrum of clinical and imaging features in a large series of non-traumatic cSAH patients. Methods: A retrospective observational study of consecutive patients with non-traumatic cSAH was performed. The Mayo Clinic Medical Records Linkage system was used to identify all patients evaluated at Mayo Clinic in Rochester with potential non-traumatic cSAH between January 1, 1996 and October 1, 2014. Clinical and radiologic data were abstracted from the comprehensive medical record. Results: We identified 88 patients [median age, 64 years (range: 25-85)] with non-traumatic cSAH. The most common causes were reversible cerebral vasoconstriction syndrome (26, 29.5%), cerebral amyloid angiopathy (23, 26.1%), indeterminate (14, 15.9%), and endocarditis (9, 10.2%). Other causes include posterior reversible encephalopathy syndrome, cerebral vein thrombosis, vasculitis, carotid occlusive disease, thrombosed developmental venous anomaly, and hyperperfusion syndrome after carotid revascularization. CAA patients commonly presented at an older age than RCVS patients (75 years vs 51 years, p<0.0001). The most common clinical presentation for CAA was sensorimotor dysfunction while thunderclap headache was the most common presentation of RCVS. Thirteen patients (14.7%) had recurrent cSAH and twelve patients (13.6%) had a subsequent intracerebral hemorrhage over a median follow up of 16 months. The risk was high among CAA patients, with subsequent lobar ICH occurring in 43.5% of cases, superficial siderosis in 95%, and recurrent cSAH in 39.1%, compared to 3.8%, 28.5% and 7.7% respectively in RCVS. Conclusions: Our study demonstrates the clinical diversity of cSAH. Older age, sensorimotor dysfunctions suggest CAA as the underlying cause. Younger age and thunderclap headache predict RCVS. Various other causes also need to be considered in the differential diagnosis. CAA patients have high rates of subsequent lobar ICH, development of superficial siderosis, and recurrent cSAH.
Abstract TMP49: Yield of Diagnostic Evaluation in Major Stroke Phenoytypes
Brown, Robert D. , Grewal, Raji P., Jiménez-Conde, Jordi , Kittner, Steven J. , Peddareddygari, Leema Reddy , Rhodes, J. , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Ay, Hakan , investigators, for the NINDS Stroke Genetics Network (SiGN), Majersik, Jennifer Juhl , Arsava, Ethem Murat , Jern, Christina , Jood, Katarina , Labovitz, Daniel , Lindgren, Arne G. , Meschia, James F. , Pera, Joanna , Rosand, Jonathan M. , Rundek, Tatjana , Southerland, Andrew M. , investigators, for the NINDS Stroke Genetics Network (SiGN)

Mayo Clinic

Stroke | July 3, 2021 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.atmp49 Get It

Background: Considerable disagreement exists among experts regarding the appropriate extent of diagnostic testing after ischemic stroke (IS). Evidence-based data guiding stroke evaluation for individual patients according to the underlying phenotype are unknown. We sought to determine the yield of cardiac and arterial evaluations for identifying an alternative major stroke etiology in patients with a given phenotype in the NINDS Stroke Genetics Network (SiGN). Methods: SiGN is a consortium of IS studies at 22 US and European sites aiming to identify stroke susceptibility genes. Adjudicators certified in Causative Classification of Stroke (CCS) system determined major etiologic stroke phenotypes based on chart review. All diagnostic data entered into the CCS software were stored in a confidential database. We determined the probability of identifying an alternative major abnormality based on cardiac (history, EKG, echocardiography) and arterial [intracranial (IC), extracranial (EC)] evaluations in 3 stroke phenotypes: lacunar infarct (LI), large artery atherosclerosis (LAA), and cardiac embolism (CE). Proportions of alternative major etiologies were calculated in patients with complete evaluations in each phenotype. Results: The analyses included 15720 patients. Among these, 2299 had phenotypic subtype of LI (1660 with cardiac and 1691 with arterial evaluations); 4228 had CE (2451 with arterial evaluation); and 2613 had LAA (2047 with cardiac evaluation). Cardiac evaluation revealed a major cardiac source of embolism in 12.3% of patients with LI and 20.3% with LAA. Echocardiography demonstrated an additional major structural cardiac source not seen by history/examination/EKG in 1.9% and 1.6% in LI and LAA respectively. Arterial evaluation led to the identification of ≥50%ipsilateral stenosis in 13.5% (IC: 8.9%, EC: 5.8%) of patients with LI and 17% (IC: 8.1%, EC: 11.3%) of those with CE. In LI patients with complete cardiac and vascular evaluations, 24.1% had an alternative major stroke etiology. Conclusions: A considerable proportion of IS patients with LI, LAA, and CE harbor an alternative major etiology. In the future, these results can be used to generate evidence-based and cost-effective evaluation and management strategies.
Abstract 44: Associations of Atrial Fibrillation, Neuroimaging Measures of Cerebrovascular Disease and Alzheimer’S Disease-related Pathology, and Cognitive Impairment
Graff‐Radford, Jonathan , Roberts, Rosebud O., Madhavan, Malini , Cha, Ruth, Lowe, Val J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Rabinstein, Alejandro A. , Vemuri, Prashanthi , Kantarci, Kejal , Mielke, Michelle M. , Senjem, Matthew L. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 46 | Issue: suppl_1 | Pages: No page available

10.1161/str.46.suppl_1.44 Get It

The objective of this study was to investigate the cross-sectional associations of atrial fibrillation with neuroimaging measures of cerebrovascular disease and Alzheimer’s disease-related pathology, and their interaction with cognitive impairment. MRI scans of non-demented individuals (n=1044) from the population-based Mayo Clinic Study of Aging were analyzed for infarctions, total grey matter, hippocampal and white matter hyperintensity volumes. A subset of 496 individuals underwent FDG and C-11 Pittsburgh compound B (PiB) PET scans. We assessed the associations of atrial fibrillation with i) categorical MRI measures (cortical and subcortical infarctions) using multivariable logistic regression models, and with ii) continuous MRI measures ( hippocampal, total grey matter, and white matter hyperintensity volumes) and FDG-PET and PiB-PET measures using multivariable linear regression models, and adjusting for confounders. Among participants who underwent MRI (median age, 77.8, 51.6% male), 13.5% had atrial fibrillation. Presence of atrial fibrillation was associated with subcortical infarctions (odds ratio [OR], 1.83; p=0.002), cortical infarctions (OR, 1.91; p=0.03), total grey matter volume (Beta [β], -.025, p<.0001) after controlling for age, education, gender, APOE e4 carrier status, coronary artery disease, diabetes, history of clinical stroke, and hypertension. However, atrial fibrillation was not associated with white matter hyperintensity volume, hippocampal volume, Alzheimer’s pattern of FDG hypometabolism or PiB uptake. There was a significant interaction of cortical infarction (p for interaction=0.004) and subcortical infarction (p for interaction =0.015) with atrial fibrillation with regards to odds of mild cognitive impairment (MCI). Using subjects with no atrial fibrillation and no infarction as the reference, the OR (95% confidence intervals [CI]) for MCI was 2.98 (1.66, 5.35;p = 0.0002) among participants with atrial fibrillation and any infarction, 0.69 (0.36, 1.33;p= 0.27) for atrial fibrillation and no infarction, and 1.50 (0.96, 2.32;p = 0.07) for no atrial fibrillation and any infarction. These data highlight that atrial fibrillation is associated with MCI in the presence of infarctions.
Abstract 205: Etiologic Ischemic Stroke Phenotypes in the NINDS Stroke Genetics Network
Ay, Hakan , Brown, Robert D. , Kittner, Steven J. , McArdle, Patrick F. , Słowik, Agnieszka , Worrall, Bradford B. , Investigators, Stroke Genetics Network, Arsava, Ethem Murat , Lee, Jin‐Moo , Rexrode, Kathryn M. , Rosand, Jonathan M. , Rundek, Tatjana , Meschia, James F. , Investigators, Stroke Genetics Network

Mayo Clinic

Stroke | July 3, 2021 | Volume: 46 | Issue: suppl_1 | Pages: No page available

10.1161/str.46.suppl_1.205 Get It

Background and Purpose: NINDS Stroke Genetics Network (SiGN) is an international consortium of ischemic stroke studies that aims to generate high quality phenotype data to identify the genetic basis of ischemic stroke subtypes. The goal of this analysis is to characterize the etiopathogenetic basis of ischemic stroke in the consortium. Methods: This analysis included 16,954 subjects with imaging-confirmed ischemic stroke from 12 US studies and 11 studies from 8 European countries. 52 trained and certified adjudicators used the web-based Causative Classification of Stroke System for etiologic stroke classification through chart reviews to determine both phenotypic (abnormal test findings categorized in major etiologic groups without weighting towards the most likely cause in the presence of multiple etiologies) and causative subtypes in each subject. Classification reliability was assessed with blinded re-adjudication of 1509 randomly selected cases. Findings: The figure shows the distribution of etiologic categories. Overall, only 40% to 54% of cases with a given major ischemic stroke etiology (phenotypic subtype) were classified into the same final causative category with high confidence. There was good agreement for both causative (kappa 0·72, 95%CI:0·69-0·75) and phenotypic classifications (kappa 0·73, 95%CI:0·70-0·75). Conclusions: This study provides high quality data on etiologic stroke subtypes and demonstrates that etiologic subtypes can be determined with good reliability in studies that include investigators with different expertise and background, institutions with different stroke evaluation protocols and geographic location, and patient populations with different epidemiological characteristics. The discordance between phenotypic and causative stroke subtypes suggests that the presence of an abnormality in a stroke patient does not necessarily mean that it is the cause of stroke.
Abstract 3884: Stroke Subtypes in Hispanic Patients in the NINDS Stroke Genetics Network (SiGN): A Comparison of Two Classification Systems
Katsnelson, Michael , Gardener, Hannah , Malik, Shaneela , Brown, Robert D. , Barrett, Kevin M. , Ossi, Raid G., Biffi, Alessandro , Helenius, Joanna, Huq, Mohammed Saiful, Weissman, Darren, Sheikh, Huma U., Saraf, Neha, Peddareddygari, Leema Reddy , Woo, Daniel , Smoller, Sylvia, Grewal, Raji P., Worrall, Bradford B. , Ay, Hakan , Kittner, Steven J. , Rundek, Tatjana , Sacco, Ralph L. , Southerland, Andrew M. , Arsava, Ethem Murat , Rexrode, Kathryn M. , Huq, Mohammed, Labovitz, Daniel , Rhodes, David , Brenner, David A. , Rosand, Jonathan M. , Arnett, Donna K. , Meschia, James F.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a3884 Get It

Objectives: Identification of gene variants of stroke subtypes is important for the development of tailored ischemic stroke therapies among various ethnic groups. Valid and reliable determination of ischemic stroke subtype is essential for achieving this goal and to standardize a classification scheme across multi-center studies and different populations. Causative Classification System for Ischemic Stroke (CCS) is a novel computerized subclassification tool developed to improve reliability and accuracy of classifying stroke types. The CCS algorithm relies on both phenotypic and causative stroke variables. A Hispanic subset of the SiGN, an important and distinct target population with greater risk of certain stroke subtypes, was evaluated with Trial of Org 10172 in Acute Stroke Treatment (TOAST) and CCS and the agreement between the two classification systems was analyzed. Methods: Over 6000 subjects at 15 sites across US and Europe were enrolled, with TOAST and CCS locally adjudicated. Blood collection and central data quality control (10% central readjudication) were performed on all participants. A subset of Hispanics was analyzed for the purpose of this study and the agreement between the TOAST and CCS were assessed by kappa statistic. Findings: Hispanics (n=595, 10.9%) compared to non-Hispanics (n=5457) were more likely to be younger (63.7 vs. 64.0), male (55% vs. 46%) and have fewer of the traditional stroke risk factors HTN (54% vs. 64%), Afib (11% vs. 14%), DM(23% vs. 25%), CAD(16% vs. 20%) and smoking(19% vs. 22%). While the TOAST showed no differences between stroke subtypes for Hispanic vs. non-Hispanics, in CCS, Hispanics were classified with more of large vessel (22% vs. 20%), cardioembolic (37% vs. 30%) and small vessel strokes (13% vs. 9%) and fewer with undetermined etiology (28% vs. 40%) as compared to non-Hispanics. TOAST and CCS offered moderate correlation across all stroke types in Hispanics: kappa of 0.66 for large artery atherosclerosis, 0.58 for cardioembolic, and 0.58 for small artery occlusion. Conclusion: CCS offers a more sensitive and accurate system for subphenotyping of strokes in Hispanics who tended to have relatively fewer risk factors and unclassified strokes. Further studies correlating the two classification systems and their relation to genotyping data are warranted.